The push for new anti-inflammatory drugs has pharmaceutical companies flocking to a previously abandoned therapy. Heidi Ledford reports on the resurrection of interleukin-1 blockers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Martinon, F. et al. Nature 440, 237?241 (2006).
Goldbach-Mansky, R. et al. N. Engl. J. Med. 355, 581?592 (2006).
Larson, C. M. et al. N. Engl. J. Med. 356, 1517?1526 (2007).
Related links
Rights and permissions
About this article
Cite this article
Ledford, H. Fever pitch. Nature 450, 600–601 (2007). https://doi.org/10.1038/450600a
Published:
Issue Date:
DOI: https://doi.org/10.1038/450600a